{
    "relation": [
        [
            "Company",
            "AMAG PHARMA\u2026",
            "AMEDISYS IN\u2026",
            "NORDIC AMER\u2026",
            "COTT CORP Q\u2026",
            "ELLIE MAE I\u2026"
        ],
        [
            "Symbol",
            "AMAG",
            "AMED",
            "NAT",
            "COT",
            "ELLI"
        ],
        [
            "Price",
            "66.20",
            "44.88",
            "15.23",
            "11.30",
            "78.83"
        ],
        [
            "%Chg",
            "+3.60%",
            "+2.87%",
            "+1.40%",
            "+0.53%",
            "+0.48%"
        ]
    ],
    "pageTitle": "Plexus Tops Estimates in 2Q - April 19, 2012 - Zacks.com",
    "title": "",
    "url": "http://www.zacks.com/stock/news/73323/plexus-tops-estimates-in-2q",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 2,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990123.20/warc/CC-MAIN-20150728002310-00168-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 849696779,
    "recordOffset": 849670112,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{25091=For the forthcoming third quarter 2012, total revenue is projected in the range of $590.0 million to $620.0 million. Plexus expects earnings to be between 60 cents and 66 cents per share, excluding any restructuring charges and including approximately 8 cents per share in stock-based compensation expenses. Currently, we expect Plexus to earn 62 cents in the third quarter., 66103=At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm., 66042=Copyright \u00a9 2015 Zacks Investment Research, 14838=by Zacks Equity Research \u00a0\u00a0Published on April 19, 2012 |}",
    "lastModified": "Mon, 03 Aug 2015 18:22:39 -0500",
    "textBeforeTable": "Income Momentum Value Growth Zacks #1 Rank Top Movers for Aug 3, 2015 Zacks #1 Rank Top Movers Zacks #1 Rank Top Movers for 08/03/15 } } document.getElementById('score_val').className = ''; document.getElementById('score_val').innerHTML = ''; document.getElementById('tab_label').innerHTML = tab_text; { else } document.getElementById('score_val').className = 'scores_val'; document.getElementById('score_val').innerHTML = 'A'; document.getElementById('tab_label').innerHTML = tab_text+ ' Score'; { if(tab_text != 'income') document.getElementById('rank_text').innerHTML = cat_uri; var cat_uri = 'View All Zacks Rank #1 '+tab_text+' Stocks'; var cat_uri = '/stocks/buy-list/'+tab_text; { function footer_text(tab_text)",
    "textAfterTable": "Company Symbol Price %Chg NCI INC NCIT 11.81 +4.98% SKYWEST INC\u2026 SKYW 17.10 +3.26% ASSURANT IN\u2026 AIZ 76.33 +2.32% PCM INC PCMI 10.29 +2.18% TRIUMPH BAN\u2026 TBK 14.25 +1.35% Company Symbol Price %Chg AMAG PHARMA\u2026 AMAG 66.20 +3.60% AMEDISYS IN\u2026 AMED 44.88 +2.87% NORDIC AMER\u2026 NAT 15.23 +1.40% COTT CORP Q\u2026 COT 11.30 +0.53%",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}